Vera Therapeutics (VERA) Common Equity (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Common Equity data on file, last reported at $499.7 million in Q1 2026.

• Quarterly Common Equity fell 6.6% year-over-year to $499.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $499.7 million (down 6.6% YoY) and the FY2025 annual result came in at $604.5 million, up 4.74% from the prior year.
• Common Equity fell to $499.7 million in Q1 2026, from $604.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $604.5 million in Q4 2025 to a low of $76.9 million in Q4 2022.
• A 5-year average of $295.1 million and a median of $289.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity soared 467.59% — and 2026, when it dropped 6.6%.
• Tracing VERA's Common Equity over 5 years: stood at $76.9 million in 2022, then soared by 32.22% to $101.7 million in 2023, then soared by 467.59% to $577.2 million in 2024, then grew by 4.74% to $604.5 million in 2025, then decreased by 17.34% to $499.7 million in 2026.
• The last three Common Equity figures came in at $499.7 million (Q1 2026), $604.5 million (Q4 2025), and $398.9 million (Q3 2025), per Business Quant data.